Qualigen Therapeutics Inc (QLGN)

Oct 27, 2025, 11:57 PM EDT - 18 days ago

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Oct 24, 2025, 3:12 AM EDT - 22 days ago

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

BTGO

Oct 23, 2025, 4:05 PM EDT - 22 days ago

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

Oct 12, 2025, 9:00 PM EDT - 4 weeks ago

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Oct 6, 2025, 7:00 PM EDT - 5 weeks ago

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Sep 30, 2025, 4:00 PM EDT - 6 weeks ago

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

FFAI

Sep 30, 2025, 7:08 AM EDT - 6 weeks ago

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Sep 19, 2025, 6:01 PM EDT - 2 months ago

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

Jul 28, 2025, 12:41 PM EDT - 3 months ago

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

May 19, 2025, 5:25 PM EDT - 6 months ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

May 1, 2025, 4:20 PM EDT - 7 months ago

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Nov 25, 2024, 5:00 PM EST - 1 year ago

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Nov 1, 2024, 9:00 AM EDT - 1 year ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Sep 26, 2024, 5:10 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces management changes.

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Sep 6, 2024, 5:00 PM EDT - 1 year ago

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

May 30, 2024, 4:00 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Nov 14, 2023, 4:30 PM EST - 2 years ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Sep 27, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 1, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Jul 24, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jun 5, 2023, 8:15 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 2, 2023, 4:30 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Apr 21, 2023, 5:46 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Mar 21, 2023, 8:35 AM EDT - 2 years ago

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Mar 15, 2023, 9:05 AM EDT - 2 years ago

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Mar 9, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Mar 8, 2023, 8:05 AM EST - 2 years ago

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Feb 1, 2023, 9:05 AM EST - 3 years ago

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Jan 24, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Jan 23, 2023, 9:02 AM EST - 3 years ago

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Jan 10, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Jan 5, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Dec 12, 2022, 8:30 AM EST - 3 years ago

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Dec 7, 2022, 9:10 AM EST - 3 years ago

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Nov 22, 2022, 9:00 AM EST - 3 years ago

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Nov 15, 2022, 7:30 AM EST - 3 years ago

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Oct 18, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics to Present at LD Micro Main Event XV